(Q91264430)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

title

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

metabolic dysfunction–associated steatotic liver disease

20 April 2020

main subject

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

2

Hans-Ulrich Häring

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

author name string

Norbert Stefan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

Kenneth Cusi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

publication date

30 August 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

The Lancet: Diabetes & Endocrinology

20 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

page(s)

313-324

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

20 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Phenotypes of prediabetes and stratification of cardiometabolic risk

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

NAFLD: a multisystem disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Nonalcoholic fatty liver disease: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Metabolically healthy obesity: the low-hanging fruit in obesity treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Causes and metabolic consequences of Fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Lipotoxicity and the gut-liver axis in NASH pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Nonalcoholic fatty liver disease: current issues and novel treatment approaches

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Geroscience: linking aging to chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Mechanisms and metabolic implications of regional differences among fat depots

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

The sexual dimorphism of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Genetics and epigenetics of NAFLD and NASH: Clinical impact

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

An extended fatty liver index to predict non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Use of Liver Imaging and Biopsy in Clinical Practice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Noninvasive Assessment of Liver Fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Serum markers detect the presence of liver fibrosis: a cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Preclinical models of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Insulin signalling and the regulation of glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

The role of hepatokines in metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

NAFLD and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Identification and characterization of metabolically benign obesity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

The impact of liver fat vs visceral fat in determining categories of prediabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Metabolically normal obese people are protected from adverse effects following weight gain

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Exome-wide association study of plasma lipids in >300,000 individuals

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Lipoprotein subclass metabolism in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

A critical review of endpoints for non-cirrhotic NASH therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Review article: new treatments in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pharmacological management of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pioglitazone for diabetes prevention in impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2818%2930154-2

7 January 2021

10.1016/S2213-8587(18)30154-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30174213%20AND%20SRC:MED&resulttype=core&format=json

20 April 2020

1 reference